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Thiamine-responsive megaloblastic anaemia (TRMA) is a rare syndrome where patients present with early onset
diabetes mellitus, megaloblastic anaemia and sensorineural deafness. This report describes a new case of TRMA
syndrome in a female patient of Portuguese descent, born to unrelated parents. The patient was found to have
a novel homozygous change R397X in exon 4 of the SLC19A2 gene, leading to a premature stop codon. The
patient’s diabetes and anaemia showed a good response to daily thiamine doses, reducing the daily insulin
dose requirement. The report further indicates that TRMA is not only limited to consanguineous or ethnically
isolated families, and should be considered as a differential diagnosis for patients presenting with suggestive
clinical symptoms.
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Thiamine-responsive megaloblastic anaemia (TRMA;
OMIM 249270), also called Roger’s syndrome, is a very
rare autosomal recessive disorder characterized by early
onset diabetes mellitus (DM), megaloblastic anaemia and
sensorineural deafness. The syndrome was first described
by Rogers et al. [1]. Other reported clinical findings in
addition to the characteristic triad include congenital heart
disease, arrhythmias, retinal degeneration, optic atrophy,
aminoaciduria, short stature, situs inversus, Polycystic
Ovarian Syndrome and stroke [2]. The disease can mani-
fest anytime between infancy and adolescence, although
often not all of the cardinal findings are manifested at on-
set. The variable phenotypic presentation of TRMA syn-
drome may cause a significant delay between the onset of
symptoms and an accurate diagnosis. Treatment is symp-
tomatic and includes pharmacological doses of thiamine
(vitamin B1), which usually corrects hematological and* Correspondence: khalid.hussain@ucl.ac.uk
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unless otherwise stated.endocrine function, but neurological manifestations do
not respond as well [1,3].
Most of the TRMA patients originated from consan-
guineous families, which is consistent with autosomal re-
cessive inheritance [4]. TRMA is caused by homozygous
mutations in the SLC19A2 gene [4], which encodes a high-
affinity thiamine transporter 1 protein (THTR-1) [5,6],
located on chromosome 1q23.3. The human TRMA gene
contains six exons that encode a protein of 497 amino
acids with 12 transmembrane domains [7]. SLC19A2 is
expressed in a wide range of human tissues including bone
marrow, liver, colon, small intestine, pancreas, brain, retina,
heart, skeletal muscle, kidney, lung, placenta, lymphocytes
and fibroblasts [8].
To date, TRMA syndrome has been reported in around
30 families worldwide. Its prevalence and incidence are
unknown. At least 43 mutations in the SLC19A2 gene
have been found to cause TRMA. Most of these mutations
lead to the production of an abnormally short, non-
functional THTR-1. Other mutations change single pro-
tein building blocks (amino acids) in THTR-1, which
disrupts the proper folding of the protein or prevents it
from reaching the cell surface. All of these mutations pre-
vent THTR-1 from bringing thiamine into the cell.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 SLC19A2 Mutation analysis: Chromatograms showing
the location of the c.1189A>T/R397X mutation in our patient,
her parents and a control. The patient is homozygous (T/T) for the
mutation, whilst both parents are heterozygous (A/T) carriers. The
wild-type allele at same location is a homozygous (A/A) as shown in
the control.
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to a non-consanguineous family of Portuguese descent. A
novel homozygous mutation was found in the SLC19A2
gene leading to a premature stop codon. The patient pre-
sented with the typical features TRMA, diabetes mellitus,
sensorineural deafness and megaloblastic anaemia.
Case presentation
A girl, 14 months of age, was born at full term, birth
weight 3.03 kg after an uneventful pregnancy and delivery
to non-consanguineous parents of Portuguese descent.
Her mother is known with thalassemia minor, her father
is healthy. A second degree paternal cousin is known with
DM type 1, diagnosed at the age of 31 years.
At the age of 10 months, our patient was referred to
the hospital because of fever of unknown origin. At that
time, she was found to have hyperglycaemia of 509 mg/dl
[28 mmol/L] and diabetic ketoacidosis (pH 7.26, HCO3
10.9, serum and urine ketones ++). Other laboratory
evaluation revealed anaemia (Hb 8.3 g/dl) and high CRP
(17.1 mg/dl). Cardiovascular examination showed an I/VI
systolic heart murmur and she presented with skin pallor.
Although treatment with insulin was started according to
the diabetic ketoacidosis protocol, there was progressive
Hb lowering (6.5 g/dl on day 10), a reticulocyte count of
54%, low neutrophil (600 with WBC 10.700/mm3) and
low platelets (29000/mm3). For this, she was treated with
a blood transfusion at that time.
In the following months there was still progressive Hb
lowering, maintaining MCV (81-87 fL), leukocytes between
7500 and 11900 with neutrophils <3000 and platelets went
down to 67000/mm3. In addition, she needed another
transfusion during febrile illness, due to CMV infection.
At 13 months of age she had ENT evaluation and hear-
ing evoked potentials were made, confirming sensorineural
deafness, which is treated with hearing prosthesis. In the
meantime, she needed progressive growing doses of insulin
(at 14 months 0.75 U/kg).
After institution of thiamine supplementation (75 mg/
day) and another blood transfusion, due to a rhinophar-
yngitis (Hb 6.4 g/dl and platelets 101000/mm3), the
haemoglobin (present: 11.5-12.9 g/dl) and WBC (present:
12000-14000/mm3 with neutrophils 4.200-4.680/microlL,
platelets >500000/mm3) increased. In addition, the pa-
tient’s blood glucose showed an improvement (HbA1c:
6.5%, 47.5 mmol/mol) and her daily insulin requirements
progressively decreased to a 2U/day (0.15 U/kg/day).
Considering the clinical history of the patient, mutational
analysis of the SLC19A2 gene was conducted. Primers were
designed to cover all six exons and their flanking intronic
regions using the online Primer 3 software [9]. The sequen-
cing reaction was conducted using the BigDye Terminator
V1.1 Cycle Sequencing kit (Applied BioSystems, Foster
City, CA, USA). The patient was found to be homozygousfor the c.1189A>T nucleotide change (protein change
R397X) in exon 4 of the SLC19A2 gene. This mutation
was absent from dbSNP database [10], 1000 Genomes
Project [11] and in Exome Variant Server [12] in the
homozygous state. The mutation leads to stop codon and
causes an early protein truncation and was predicted to be
deleterious by the online PROVEAN PROTEIN software
[13]. The c.1189A>T change is previously reported (SNP
ID: rs371383730) in the heterozygous state in a single
European-American individual on the Exome Variant
Server [12]. The parents of the patient were also found to
be heterozygous carriers for the mutation, which was ab-
sent in the control (Figure 1).
Discussion
The first case of TRMA syndrome was described in 1969
by Rogers et al. [1]. Most of the early cases which followed
have been in patients from a Middle Eastern or Asian
background. However a growing number of cases recently
report patients from non-consanguineous European back-
grounds [2,14,15]. Here we report a female patient from a
non-consanguineous Portuguese family with a homozy-
gous nonsense mutation in the SLC19A2 gene.
Thiamine plays an essential role in carbohydrate metabol-
ism and energy production reactions. Under physiological
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is transported by two high affinity carriers found in the
intestine - THTR-1 encoded by the SLC19A2 gene, and
THTR-2 encoded by the SLC19A3 gene. Both genes are
expressed in most body tissues; however the cochlear inner
hair cells, pancreatic islet cells and erythropoietic precursor
cells only express SLC19A2. Under high thiamine concen-
trations, thiamine crosses the cell membrane through
passive diffusion [8,16-18]. In TRMA syndrome the active
uptake of thiamine by carrier mediated mechanisms is dis-
rupted leading to thiamine deficiency. As most cells have a
compensatory mechanism via THTR-2, only the three
THTR-1 dependent cells are the most affected by thiamine
deficiency, and thus explain the clinical triad associated
with TRMA syndrome [19].
The high level of thiamine in pancreas is essential for
its normal endocrine and exocrine function [20].
Thiamine deficiency negatively impacts insulin regula-
tion, as the pancreatic islet cells from thiamine deficient
rats show impaired insulin secretion [21]. This is pos-
sibly due to cell death and apoptosis [22].
Thiamine is essential for normal auditory development
and function, and infants fed thiamine deficient meals
develop auditory problems [23]. The higher expression
of THTR-1 in the cochlear inner hair cells than the
outer hair cells suggests its essential role for inner hair
cell function [24]. Slc19a2 null mice show selective loss
of inner hair cells, within 1-2 weeks of being subjected
to thiamine deficient diet [25].
To date 43 mutations have been described in the
SLC19A2 gene (HGMD January 2015) [26]. Majority are
missense and nonsense changes, followed by small inser-
tions and deletions. A large intragenic deletion was also
reported by Beshlawi et al., where a 5224 base pair re-
gion in SLC19A2 was deleted in 6 patients [27]. Cases
reporting compound heterozygosity show that TRMA is
not only limited to consanguineous or ethnically isolated
families [2,14,15].
Most TRMA patients show the cardinal findings of the
syndrome; however the onset of the different symptoms
may vary [2]. Our patient developed all 3 symptoms
between 10 to 13 months of age. Furthermore the obser-
vation of other clinical symptoms in TRMA apart from
the clinical triad makes it difficult to define a clear
genotype-phenotype relationship. Visual impairments,
cardiac anomalies and neurological impairments are
seen in some patient with TRMA and not others, des-
pite carrying the same causative mutation [28-30].
Treatment with high thiamine doses produces a variable
response in patients [31]. Usually this corrects for haem-
atological and endocrinal findings, normalizing patient’s
anaemia and hyperglycaemia overtime. However patients
have been reported where insulin therapy was still required
[31]. Thiamine supplementation becomes ineffective oncethe patient reaches puberty; follow up studies report pa-
tients requiring insulin therapy and regular blood transfu-
sion during adulthood [7]. Low thiamine concentrations
may cause cell death by apoptosis in TRMA patient fibro-
blast cells [22]. This may therefore lead to a reduced re-
serve of pancreatic beta cells, and as suggested by Valerio
and colleagues, may be insufficient to meet the changing
physiological demands of insulin during puberty [32]. Our
patient required progressively increasing doses of insulin to
control her blood glucose levels prior to TRMA diagnosis.
This was reduced to a single dose of 2U/day (0.15U/kg/
day) of insulin within 6 months of beginning on a thiamine
dose of 75 mg/day.
Hearing loss in SLC19A2 knockout mice can be re-
versed when fed with a high thiamine diet following a
thiamine free diet [33]. However in humans the effect of
thiamine deficiency seems to be irreversible for hearing
loss [31]. One TRMA patient diagnosed without the devel-
opment of hearing loss at one month of age, was started
on early thiamine therapy, and still had no signs of hearing
loss in the follow up period at 30 months of age [34]. Early
intervention in this case could have occurred before the
damage of thiamine deficiency affected hearing. It may
still be possible that the patient goes on to develop hearing
loss later in life. Patients with compound heterozygote
mutations are reported to have a milder phenotype, with
less severe hearing loss [2].Conclusion
In summary we report a new case of TRMA syndrome in
a patient from a non-consanguineous European family of
Portuguese descent. The causative mutation, c.1189A>T/
R397X is a novel nonsense mutation, introducing a pre-
mature stop codon in exon 4 for the SLC19A2 gene. In-
creasing number of cases are reported in European non
consanguineous families, and therefore despite being rare,
TRMA should be considered as a differential diagnosis in
patients presenting with suggestive clinical symptoms.
The patients generally respond well to thiamine supple-
mentation, which keeps the condition under control – al-
though only temporarily till the patient reaches puberty.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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